Loading the section…
The price of Supernus Pharmaceuticals, Inc. (SUPN) on October 9, 2026 is 42.67 USD, +1.26% on the day. Over 52 weeks the stock traded between 40.51 USD and 59.68 USD; the price now sits 11% of the way up that range. Over the past year the price changed by -11.10%. Market capitalization is 2.48 billion USD, rank 62 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): −11.80 %
Supernus Pharmaceuticals, Inc. trades on Nasdaq under the ticker SUPN. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks SUPN has traded between 40.51 $ and 59.68 $. As of 9 October 2026 the price stood 11.27 % of the way from the 52-week low to the high.
Over one year SUPN shares fell 11.10 %; over six months they fell 15.81 %. Volatility over 90 days is 32.79 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 3.2, below the sector median of 4.0. Price to book is 2.3, below the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 42.18 | 43.14 | 42.15 | 42.67 | 643,800 |
| 8 October 2026 | 42.41 | 43.41 | 41.14 | 42.14 | 684,200 |
| 7 October 2026 | 42.24 | 43.38 | 42.24 | 43.05 | 571,000 |
| 6 October 2026 | 42.86 | 43.12 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
No news about this security in English yet.
Supernus Pharmaceuticals, Inc. (SUPN) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 776.8m $, net income was -29.0m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850, US
Supernus Pharmaceuticals, Inc. reported revenue of 777M $ and a net loss of 29M $ over the last four quarters. Net margin is −3.74 %. Revenue changed by +16.29 % year over year. Earnings per share are −0.51 $. Market capitalisation is 2.5B $.
SUPN has a return on equity of −2.69 %, above the sector median of −41.68 %. Return on assets is −1.93 %, above the sector median of −32.11 %. Operating margin is −7.77 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 41.40 |
| 42.83 |
| 748,300 |
| 5 October 2026 | 42.38 | 43.20 | 42.38 | 42.76 | 1M |
| 2 October 2026 | 42.47 | 43.15 | 41.88 | 42.38 | 739,800 |
| 1 October 2026 | 43.21 | 43.69 | 42.15 | 42.18 | 424,600 |
| 30 September 2026 | 44.03 | 44.18 | 43.03 | 43.04 | 685,600 |
| 29 September 2026 | 44.39 | 44.93 | 43.20 | 43.97 | 551,600 |
| 28 September 2026 | 42.59 | 44.61 | 42.38 | 44.60 | 728,100 |
| 25 September 2026 | 43.21 | 43.69 | 42.65 | 42.66 | 607,600 |
| 24 September 2026 | 43.22 | 44.00 | 42.77 | 43.29 | 589,000 |
| 23 September 2026 | 43.66 | 44.46 | 43.14 | 43.39 | 544,500 |
| 22 September 2026 | 43.04 | 44.25 | 42.82 | 43.75 | 667,600 |
| 21 September 2026 | 42.00 | 42.97 | 41.68 | 42.78 | 635,700 |
| 18 September 2026 | 42.89 | 42.89 | 41.60 | 42.00 | 1M |
| 17 September 2026 | 41.66 | 43.40 | 41.46 | 42.92 | 559,800 |
| 16 September 2026 | 41.31 | 41.84 | 40.75 | 41.38 | 787,800 |
| 15 September 2026 | 41.49 | 41.75 | 40.51 | 41.28 | 669,200 |
| 14 September 2026 | 42.16 | 42.54 | 41.23 | 41.49 | 678,100 |